MX2014015615A - Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. - Google Patents

Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.

Info

Publication number
MX2014015615A
MX2014015615A MX2014015615A MX2014015615A MX2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A
Authority
MX
Mexico
Prior art keywords
iron
patients
reduce
increase
ferric citrate
Prior art date
Application number
MX2014015615A
Other languages
English (en)
Spanish (es)
Inventor
Enrique Poradosu
Ron Bentsur
James F Oliviero Iii
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of MX2014015615A publication Critical patent/MX2014015615A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014015615A 2012-06-21 2013-06-21 Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. MX2014015615A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15
PCT/US2013/047134 WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Publications (1)

Publication Number Publication Date
MX2014015615A true MX2014015615A (es) 2015-03-20

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015615A MX2014015615A (es) 2012-06-21 2013-06-21 Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.

Country Status (19)

Country Link
US (3) US20130345303A1 (enExample)
EP (3) EP2863906B1 (enExample)
JP (4) JP2015535209A (enExample)
KR (2) KR20200103855A (enExample)
CN (2) CN113244209A (enExample)
AU (2) AU2013278000A1 (enExample)
BR (1) BR112014032049A2 (enExample)
CA (1) CA2876982A1 (enExample)
DK (1) DK3730136T3 (enExample)
EA (1) EA201590062A1 (enExample)
ES (2) ES2970050T3 (enExample)
FR (1) FR25C1043I1 (enExample)
HK (1) HK1214503A1 (enExample)
IL (1) IL236356A0 (enExample)
MX (1) MX2014015615A (enExample)
NO (1) NO2025048I1 (enExample)
PL (1) PL3730136T3 (enExample)
SG (2) SG10201805177PA (enExample)
WO (1) WO2013192565A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140016438A (ko) 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
RU2728778C2 (ru) 2013-06-05 2020-07-31 Трисида, Инк. Протон-связывающие полимеры для перорального введения
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
AU2014341975A1 (en) * 2013-11-04 2016-05-19 Keryx Biopharmaceuticals, Inc. Ferric citrate for reducing cardiac failure in chronic kidney disease patients
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
KR102625115B1 (ko) 2014-12-10 2024-01-12 트리시다, 인크. 경구 투여용 양성자-결합 폴리머
JP2018507260A (ja) * 2015-03-04 2018-03-15 ケリク バイオファーマシューティカルス， インコーポレーテッド 鉄欠乏性貧血の治療におけるクエン酸第二鉄の使用
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
IL308673A (en) 2016-05-06 2024-01-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019059172A1 (ja) 2017-09-19 2019-03-28 日本たばこ産業株式会社 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
SG11202003451UA (en) 2017-11-03 2020-05-28 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
CN113613662A (zh) 2018-10-29 2021-11-05 法码科思莫斯控股有限公司 用羧基麦芽糖铁治疗铁缺乏
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000067929A (ko) * 1996-07-19 2000-11-25 나가타 코이치 고인혈증 치료제
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
KR20080037083A (ko) 2005-08-18 2008-04-29 글로보아시아 엘엘씨 약학용 등급의 유기 철 화합물, 그 용도 및 이의 제조 방법
KR20180077337A (ko) * 2006-01-06 2018-07-06 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
CN105055446B (zh) * 2006-01-30 2022-06-03 宝龄富锦生技股份有限公司 逆转、防止、延迟或稳定软组织钙化的方法
KR20140016438A (ko) 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태

Also Published As

Publication number Publication date
FR25C1043I1 (fr) 2026-01-02
JP2018138562A (ja) 2018-09-06
SG10201805177PA (en) 2018-07-30
EP2863906B1 (en) 2020-03-18
EA201590062A1 (ru) 2016-02-29
KR20150036131A (ko) 2015-04-07
EP2863906A2 (en) 2015-04-29
EP3730136A1 (en) 2020-10-28
NO2025048I1 (no) 2025-11-06
SG11201408521WA (en) 2015-01-29
AU2018203205A1 (en) 2018-05-31
BR112014032049A2 (pt) 2017-07-25
EP4335436A3 (en) 2024-05-15
US20140234416A1 (en) 2014-08-21
US20150079168A1 (en) 2015-03-19
ES2796254T3 (es) 2020-11-26
HK1210013A1 (en) 2016-04-15
WO2013192565A2 (en) 2013-12-27
PL3730136T3 (pl) 2024-03-25
JP2022070945A (ja) 2022-05-13
EP3730136B1 (en) 2023-12-27
CA2876982A1 (en) 2013-12-27
ES2970050T3 (es) 2024-05-24
CN113244209A (zh) 2021-08-13
DK3730136T3 (da) 2024-01-22
US20130345303A1 (en) 2013-12-26
KR102150135B1 (ko) 2020-08-31
JP2015535209A (ja) 2015-12-10
JP2020100638A (ja) 2020-07-02
EP4335436A2 (en) 2024-03-13
WO2013192565A3 (en) 2015-10-15
AU2018203205B2 (en) 2020-03-12
HK1214503A1 (zh) 2016-07-29
AU2013278000A1 (en) 2015-01-22
KR20200103855A (ko) 2020-09-02
IL236356A0 (en) 2015-02-26
CN104884055A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
MX2016005734A (es) Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
MY183637A (en) Compounds and uses thereof for the modulation of hemoglobin
EA201890278A1 (ru) Антитела к pd-l1
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
BR112012033044A2 (pt) composição de precursor de diálise
MY191087A (en) Compounds and uses thereof for the modulation of hemoglobin
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
NZ702469A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
EA201690528A1 (ru) Способы лечения злокачественной опухоли непрерывной инфузией кофермента q10
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
EA201490549A1 (ru) Применение белка c-met для прогнозирования эффективности антител к фактору роста гепатоцитов (фрг) у пациентов с раком пищевода и желудка
BR112014009414A2 (pt) uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
RU2014145887A (ru) Комбинированная терапия с использованием антител против mif и химиотерапевтических средств
NZ725920A (en) Use of ferric citrate in the treatment of chronic kidney disease patients